CohBar Engages LifeSci Advisors as Investor Relations Partner

Comprehensive Program to Focus on Raising Company’s Visibility Ahead of Potential Value-Creating Milestones

MENLO PARK, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that it has engaged LifeSci Advisors LLC ("LifeSci"), a leading New York-based investor relations consultancy serving life science companies, to implement a comprehensive investor outreach program that will include analyst and investor targeting/outreach, non-deal roadshows, corporate communications, and Key Opinion Leader (KOL) events in the field of mitochondria based therapeutics and age-related diseases.      

“The decision to engage LifeSci Advisors advances our strategic initiative to expand awareness of CohBar in the investment community, particularly among institutional investors,” said Simon Allen, Chief Executive Officer of CohBar. “The team at LifeSci, with its extensive Wall Street experience, brings a unique set of capabilities that will enable us to present our compelling story to a wide audience of sophisticated prospective investors, both in the U.S. and internationally.”

About CohBar
CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction, including nonalcoholic steatohepatitis (NASH), obesity, type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the company and its founders have discovered more than 100 MDPs. For additional company information, please visit www.cohbar.com.

About LifeSci Advisors
LifeSci Advisors is a division of LifeSci Partners (www.lifescipartners.com), a leading provider of consulting services for life sciences clients in the areas of investor relations, public relations, corporate communications, executive search, strategic partnering and capital markets advisory. LifeSci combines deep domain expertise and decades of experience in capital markets and communications with a global network to deliver unparalleled services to clients. LifeSci Advisors is the largest investor relations consultancy in the life sciences industry, founded to provide companies with a multi-faceted approach to investor communications and outreach. LifeSci Advisor’s team of financial services and investor relations specialists synergistically pair with LifeSci Public Relations’ team of MDs and PhDs, positioning the firm to best communicate its clients’ scientific, R&D, regulatory and commercial strategies to diverse audiences. LifeSci Partners’ addition of executive search, strategic partnering and capital markets advisory capabilities provides fully integrated business solutions for life sciences clients across all stages of development.

Forward-Looking Statements 
This news release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include CohBar’s plans and expectations for investor outreach and corporate communications. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated by CohBar. These risks and uncertainties include, among other things, difficulty in attracting the attention of securities analysts, industry participants and investors, and our inability to control the content of any research or reports that industry or securities analysts publish about our business, market or competitors. Additional risks and uncertainties include CohBar’s ability to retain key personnel, expand its research operations, and obtain financing necessary to continue its operations and fund its candidate programs. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com.

You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.

Contacts:
Jon Stern, COO
CohBar, Inc.
(650) 446-7888
jon.stern@cohbar.com

Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Released September 25, 2018